Analysis of subsequent therapy in Japanese patients with hormone receptor ‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.

CONCLUSIONS: The types of first subsequent therapy received by Japanese patients in the palbociclib plus ET and placebo plus ET groups were similar. Further evaluation of subsequent therapy data in the real-world setting is warranted considering the small sample size of this analysis.
PMID: 33085032 [PubMed - as supplied by publisher]

Source: Breast Cancer - October 21, 2020 Category: Cancer & Oncology Authors: Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Ohtani S, Shimizu C, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M Tags: Breast Cancer Source Type: research